Bioceres Crop Solutions Corp.
Bioceres Crop Solutions develops and commercializes agricultural inputs and technologies for farmers, distributors, cooperatives, dealers and agricultural companies. Headquartered in Rosario, Argentina, it markets products in more than 45 countries, primarily in South America, the United States and Europe. Its three segments are crop protection, seed and integrated products, and crop nutrition. Products include adjuvants and biological pest-control solutions; seed traits, germplasm and seed-treatment packs; and inoculants, biofertilizers, micro-beaded fertilizers and biostimulants. Bioceres sells through international subsidiaries and a sales and marketing team, and works with more than 1,600 dealers and distributors. It also earns money through licensing technology, including the HB4 trait, and through distribution agreements under which partners sell certain biological products.
No SEC Form 4 filings for $BIOX in the last 30 days.
See all $BIOX insider activity →Bioceres reported Q1 revenue of $53.8M, down 22.1% Y/Y. Gross profit fell 39% to $18.8M, while net loss widened to $10.8M from $4.7M in the prior-year quarter. Adjusted EBITDA declined to $5.3M from $13.9M.
Bioceres Crop Solutions reported an 18% revenue decline in Q4 2026, driven by international business and a seed business model reconfiguration. Management reduced SG&A by 19% and aims for a 40% gross margin in 2027. The company faces ongoing litigation and debt restructuring challenges, with $118.6 million in secured notes classified as short-term debt. Core product categories showed improved gross profit despite top-line headwinds.
Bioceres Crop Solutions Corp. (BIOX) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Bioceres Crop Solutions Bioceres Crop Solutions Reports Fiscal Fourth Quarter and Full-Year 2026 Financial and Operating Results Total revenues were $55.9 million in 4Q26 and $238.3 million in FY26 ROSARIO, Argentina – September 14, 2026 – Bioceres Crop Solutions Cor
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning BIOX (Bioceres Crop Solutions Corp.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 3 bearish.
Recent BIOX coverage spans earnings and financial news.
The disappointing earnings are likely to push the stock lower.
Bioceres Crop Solutions reported an 18% revenue decline in Q4 2026, driven by international business and a seed business model reconfiguration. Management reduced SG&A by 19% and aims for a 40% gross margin in 2027. The company faces ongoing litigation and debt restructuring challenges, with $118.6 million in secured notes classified as short-term debt. Core product categories showed improved gross profit despite top-line headwinds.
Earnings beat on loss narrowing and positive Adjusted EBITDA may support short-term price upside.
Earnings beat on adjusted EBITDA and debt restructuring may support short-term price stability, but revenue decline and high debt pose downside risk.
Earnings beat on adjusted EBITDA but revenue flat; loss per share wider than expected may pressure price.
AlphAI scores every news story that mentions BIOX with an AI model for sentiment and relevance, and aggregates insider trades from Bioceres Crop Solutions Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Bioceres reported Q1 revenue of $53.8M, down 22.1% Y/Y. Gross profit fell 39% to $18.8M, while net loss widened to $10.8M from $4.7M in the prior-year quarter. Adjusted EBITDA declined to $5.3M from $13.9M.
Bioceres Crop Solutions reported an 18% revenue decline in Q4 2026, driven by international business and a seed business model reconfiguration. Management reduced SG&A by 19% and aims for a 40% gross margin in 2027. The company faces ongoing litigation and debt restructuring challenges, with $118.6 million in secured notes classified as short-term debt. Core product categories showed improved gross profit despite top-line headwinds.
Bioceres Crop Solutions Corp. (BIOX) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Bioceres Crop Solutions Bioceres Crop Solutions Reports Fiscal Fourth Quarter and Full-Year 2026 Financial and Operating Results Total revenues were $55.9 million in 4Q26 and $238.3 million in FY26 ROSARIO, Argentina – September 14, 2026 – Bioceres Crop Solutions Cor
Bioceres (BIOX) reported a challenging fiscal year 2026 with an 18% revenue decline to $238M, driven by seed business reconfiguration and lower crop protection performance. Quarterly revenue was $55.9M, with crop nutrition revenue growing 36%. Adjusted EBITDA improved to $600K from a $9.6M loss, aided by a 19% reduction in SG&A expenses. The company faces litigation and debt restructuring challenges, with total financial debt at $225.9M. Management targets a 40% gross margin for fiscal 2027 and
Bioceres Crop Solutions reported Q4 2026 revenue of $55.9M, flat YoY, and a net loss of $0.50 per share, missing estimates. Adjusted EBITDA turned positive at $0.6M. Full-year revenue fell 18% to $238.3M. CEO Federico Trucco emphasized business simplification and profitability. BIOX stock closed at $0.43, down 1.68% post-earnings.
Agriculture Investment Group Corp. and Granosur Holding Limited have reduced their combined stake in Bioceres Crop Solutions Corp. (BIOX) to 9.05%, owning 5,776,807 ordinary shares. This reduction followed open-market sales of over 1 million shares between March 13 and March 20, 2026, at prices ranging from $0.36 to $0.53 per share. The amended Schedule 13D filing indicates these are secondary-market trades and the reporting persons currently have no plans for corporate actions.
Bioceres Crop (BIOX) delivered earnings and revenue surprises of -200.00% and -18.37%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
The most oversold stocks in the materials sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.
Bioceres Crop (BIOX) delivered earnings and revenue surprises of 80% and 3.56%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
